European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
Characteristics and prognosis of ovarian metastatic tumors: review of a single-institution experience
1 Department of Obstetrics and Gynecology, Oncology Unit, Bakirkoy Woman and Children Training and Research Hospital, Istanbul
2 Department of Obstetrics and Gynecology, Bakirkoy Woman and Children Training and Research Hospital, Istanbul (Turkey)
Eur. J. Gynaecol. Oncol. 2013, 34(1), 75–78;
Published: 10 February 2013
Background: To evaluate the clinico-pathological characteristics and role of surgery in patients with ovarian metastasis. Materials and Methods: Clinical data from 51 patients with pathologically confirmed ovarian metastasis were reviewed. Results: Ovarian metastasis accounted for 14% of all malignant ovarian neoplasms (51/364). Of the 51 metastatic ovarian tumor cases, 24 originated from gynecologic malignancies, while 27 originated from non gynecologic malignancies. Optimal cytoreduction was performed in 88% and 37% of patients with metastases of gynecologic and non-gynecologic origin, respectively. Patients with ovarian metastasis had a two-year survival rate in 82% of the gynecologic group and 70% of the non-gynecologic group (p = 0.35). The five-year survival rate of patients with non-gynecologic tumor origin (29%) was significantly worse (p = 0.04) than the survival rates of those with tumors of gynecologic origin (61%). In the non-gynecologic group, the five-year survival rates were significantly different between patients who were performed optimal cytoreductive surgery vs those without this procedure (42% and 20%, respectively; p = 0.04). Conclusion: Although complete surgical resection is not achievable in approximately two-thirds of patients with metastases of non-gynecological origin, optimal tumor cytoreduction appears to improve survival, which is statistically significant in all patients with ovarian metastatic tumors.